UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION
STATEMENT UNDER SECTION 14(d)(4) OF THE
SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
Hardinge Inc.
(Name of Subject Company)
Hardinge Inc.
(Name of Person Filing Statement)
Common Stock, $0.01 par value per share
(Title of Class of Securities)
412324303
(CUSIP Number of Class of Securities)
Richard L. Simons
President & Chief Executive Officer
Hardinge Inc.
One Hardinge Drive
Elmira, New York 14902-1507
Telephone: 607-378-4107
(Name, address and telephone numbers of person authorized to receive notices and communications on behalf of the persons filing statement)
Copies to:
Trevor S. Norwitz, Esq.
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, New York 10019
Telephone: (212) 403-1000
o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
This Amendment No. 3 to the Schedule 14D-9 ("Amendment No. 3"), filed with the Securities and Exchange Commission (the "SEC") on May 19, 2010, amends and supplements the Schedule 14D-9 originally filed with the SEC on April 5, 2010 and amended by Amendment No. 1 on April 6, 2010 and Amendment No. 2 on May 19, 2010 (as amended, the "Statement"), by Hardinge Inc., a corporation existing under the laws of New York ("Hardinge" or the "Company"). The sole purpose of this Amendment No. 3 is to file additional exhibits and update the exhibit index of the Statement accordingly.
"Item 9.Exhibits" of the Statement is hereby amended and supplemented by adding the following exhibits:
Exhibit Number |
Description | |
---|---|---|
(a)(8) | Letter to shareholders of Hardinge, dated May 19, 2010. | |
(a)(9) | Letter to employees of Hardinge, dated May 19, 2010. |
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
HARDINGE INC. | ||||
By: |
/s/ RICHARD L. SIMONS Name: Richard L. Simons Title: President and Chief Executive Officer |
Dated: May 19, 2010